The promise of islet cell transplantation cannot be fully realized in the absence of improvements in engraftment of resilient islets. The marginal mass of islets surviving the serial peritransplant insults may lead to exhaustion and thereby contribute to an unacceptably high rate of intermediate and long-term graft loss. Hence, we have studied the effects of treatment with alpha 1-antitrypsin (AAT) in a syngeneic nonautoimmune islet graft model. A marginal number of syngeneic mouse islets were transplanted into nonautoimmune diabetic hosts and islet function was analyzed in control and AAT treated hosts. In untreated controls, marginal mass islet transplants did not restore euglycemia. Outcomes were dramatically improved by short-term AAT treatment. Transcriptional profiling identified 1,184 differentially expressed transcripts in AAT-treated hosts at 3 d posttransplantation. Systems-biology-based analysis revealed AAT down-regulated regulatory hubs formed by inflammation-related molecules (e.g., TNF-α, NF-κB). The conclusions yielded by the systems-biology analysis were rigorously confirmed by QRT-PCR and immunohistology. These data suggest that short-term AAT treatment of human islet transplant recipients may be worthy of a clinical trial.
The promise of islet cell transplantation cannot be fully realized in the absence of improvements in engraftment of resilient islets. The marginal mass of islets surviving the serial peritransplant insults may lead to exhaustion and thereby contribute to an unacceptably high rate of intermediate and long-term graft loss. Hence, we have studied the effects of treatment with alpha 1-antitrypsin (AAT) in a syngeneic nonautoimmune islet graft model. A marginal number of syngeneic mouse islets were transplanted into nonautoimmune diabetic hosts and islet function was analyzed in control and AAT treated hosts. In untreated controls, marginal mass islet transplants did not restore euglycemia. Outcomes were dramatically improved by short-term AAT treatment. Transcriptional profiling identified 1,184 differentially expressed transcripts in AAT-treated hosts at 3 d posttransplantation. Systems-biology-based analysis revealed AAT down-regulated regulatory hubs formed by inflammation-related molecules (e.g., TNF-α, NF-κB). The conclusions yielded by the systems-biology analysis were rigorously confirmed by QRT-PCR and immunohistology. These data suggest that short-term AAT treatment of human islet transplant recipients may be worthy of a clinical trial. type 1 diabetes | insulin | nonobese diabetic mice | immune response I n theory, islet transplantation offers great hope for eluding the complications of type 1 diabetes (T1D) or whole-organ pancreas transplantation. However, the clinical application of islet transplantation has been slowed by the inability to use islets from a single donor to restore euglycemia, even short term, in most islet allograft recipients and by the unacceptably high 5 y failure rate even for islet transplants that function at 1 y posttransplantation (1) . As a result of nonimmunologic processes, many islets perish during harvest, purification, and shortly following transplantation (2, 3) . Moreover, the marked nonimmunologic loss of islets may render the recipient prone to β-cell exhaustion long term (4) . A multicenter review of autologous islet transplant outcomes reveals 31% of the autografts lose function within 7 d and 50% of the grafts that function at 7 d lose function within a year (5) . Until these potentially linked problems, early nonimmunologic islet cell death, and failure to obtain enduring graft function are resolved, whole-organ transplantation, an intrusive and complication-prone procedure, will remain the transplant of choice because a single whole organ provides islet cell mass, sufficient to control hyperglycemia short and long term.
Alpha 1-antitrypsin (AAT), an acute phase reactant serine protease inhibitor with antiinflammatory, antileukocyte migratory, antithrombotic, and antiapoptotic effects (6-9), exerts cytoprotective effects upon islets in vitro (8, 10) . As expression of AAT sharply rises in response to inflammation, AAT may function to limit the duration and magnitude of inflammation (11) . Furthermore, short-term AAT treatment restores euglycemia and self-tolerance to islets in overtly T1D nonobese diabetic (NOD) mice. As a means to test strategies for prevention of nonimmune islet graft loss, we studied the impact of AAT upon the fate of marginal mass syngeneic islet transplants in a highly reproducible mouse model.
Results

Beneficial Effects of AAT Treatment on Marginal Size Syngeneic Islet
Transplants. Transplantation of 250 C57BL/6 syngeneic wild-type islets renders 20-27% of diabetic mice euglycemic (12, 13) . In contrast, euglycemia was restored in 75% of recipients of islets that were engineered to overexpress A20 (13), whereas pancaspase inhibitor therapy restored euglycemia in 90% of treated vs. 27% of control subjects (12) . Herein we demonstrate that 100% of AAT-treated hosts (2 mg/mouse every third day × 5 doses; n = 10) rendered diabetic by administration of streptozotocin (STZ) and transplanted with approximately 200 islets, manifest satisfactory day-3 islet transplant function, but only 10% of vehicle-treated controls (n = 10) become transiently euglycemic at day 3 posttransplantation. Moreover, 70% of AAT treated, but none of untreated control, diabetic syngeneic mouse recipients remained normoglycemic for 60 d posttransplantation ( Table 1 ). Note that aliquots of same islet harvested pools were given to both AAT-treated and control hosts. The detailed time course for blood glucose levels in pre-and posttransplantation in AAT-treated and control hosts is shown in Fig. S1 . To further analyze the effect of AAT, we compared insulin content of nontransplanted islet preparations and those harvested 3 d posttransplantation from untreated and AAT-treated hosts (Fig. 1) . Clearly AAT treatment afforded great protection to islet transplants (P value <0.0001) with negligible loss compared with freshly prepared islets.
Distinctive Effects of AAT upon Transcriptional Profiles of Marginal
Size Islet Transplants. As islet graft failure was noted in 90% of controls but none in AAT-treated hosts at day 3, transcriptional profiles of islet grafts from three control and three AAT-treated mice were analyzed at this time point using Affymetrix Mouse 430 2.0 GeneChips. Syngeneic islet transplants were placed under the renal capsule of nonautoimmune C57BL/6 diabetic mice and resected 3 d after administration of AAT or control vehicle.
All arrays (three per group) demonstrated high quality on the basis of scaling factor, average background, percent present calls, and 3′/5′ RNA ratio. After normalization and preprocessing, 1,184 transcripts were identified as significantly differentially expressed with a fold change (FC) >1.5 and lower confidence bound (LCB) >1.2 in islets of AAT-treated mice at day 3 posttransplantation compared with the control group. A total of 1,042 transcripts were down-regulated and 142 were up-regulated by AAT treatment. A hierarchical cluster of the top differentially expressed genes is shown in Fig. 2 . A significant number of genes down-regulated by AAT treatment encoded proteins linked to inflammatory processes, most prominently chemokines and chemokine receptors (CCR5, CCL7, CCL2, CCL8, and CCL12; Fig. 2 ), which may be a reflection of less infiltration by inflammatory cells.
Impact of AAT Treatment on Islet Transplants: Gene Ontology and Pathway Enrichment Analysis. To gain further insight into the functional consequences of altered gene expression in AATtreated islets, we performed gene ontology (GO) and pathway and interactive network enrichment analysis. GO enrichment analysis, using Database for Annotation, Visualization and Integrated Discovery (DAVID) (14) , identified clusters of inflammatory response, cell activation, immune response, and chemotaxis-related GO categories as significantly affected by AAT treatment ( Table 2 ). The inflammatory response cluster, which includes defense response, acute inflammatory response, and response to external stimulus gene ontologies, achieved a statistically highly relevant enrichment score of >10, which is highly suggestive of a role for AAT in affecting these biological processes either directly or indirectly by reducing stimuli that attract and/or activate immune cells (Table 2) .
Additionally, we probed for canonical pathway enrichment using the Ingenuity Pathway Analysis (IPA) tools and calculated the P value for each pathway according to the fit of AAT differential regulation data to the IPA database. The pathway enrichment analysis indicates overall that the principal effect of AAT is to down-regulate innate immune/inflammation-related pathways including IL-6, IL-8, IL-10, chemokine signaling, dendritic cell maturation signaling, and cross-talk between dendritic cells and natural killer cells (Fig. 3A) . That most of the differentially regulated genes (∼90%) were down-regulated by AAT treatment in significantly effected pathways suggests a role for AAT in down-regulating inflammatory processes. Using quantitative real-time PCR (QRT-PCR), we validated the microarray results showing down-regulation for each of the tested targets (CD36, IL7R, CCL17, CCL18, and CCL8 (Fig. S2 ).
AAT Treatment Impacts Key Nodes Within Inflammation Networks.
To generate an integrated view of effects of AAT on islets, we performed interactive network analysis using IPA 5.0 software. This analysis generates an interaction network based on known functional interactions such as protein-protein interactions or gene regulation interactions and demonstrates the interconnectivity between genes. Ten different networks were identified with a score greater than 40 (P value = 10 −40 ). Score is derived from the P value of one-tailed Fisher test [score = −log (P value)] and indicates the likelihood of focus genes to appear together in the network due to random chance. A score of 2 or higher has at least a 99% probability of not being generated by random chance alone.
Three networks related to inflammation and immune response out of 10 networks (score >40) were merged together to generate an integrated picture of biological relationships among these pathways. The merging of the three significantly effected networks generated a complex network with regulatory hubs formed by inflammation-related molecules (e.g., TNF-α and NF-κB), chemokines/interleukins (e.g., CCL2, IL4, IL13, and IL12), and immune response [CD86, CD40, and toll-like receptor (TLR)-4] as well as diabetes-related genes (IGF1). The top 20 ranked focus gene hubs are shown in Fig. 3B . The focus gene hubs are likely critical for overall function of the network and, thus interrupted expression of such genes by therapeutic intervention is anticipated to perturb the whole network. Whereas individual fold changes of focus gene hubs were not always significant, their number of interactions (centrality) within the networks implicates them as key mediators of AAT effects. TNF-α emerged as the highest connected gene, accounting for 44% of the connections, suggesting its critical role in curative effects. Because most of the genes surrounding these hubs are downregulated by AAT, it is highly likely that these focus molecules and pathways are inhibited by AAT or that infiltration of immune cells expressing such genes is reduced by AAT.
Using the QRT-PCR methods, we have validated some important nodes/genes from top 20 focus gene hubs including CCL2, PTGS2, and IGF1, thereby depicting acute effects of AAT. Evaluation of TNF-α and TLR4 expression by QRT-PCR does not appear to significantly change, suggesting that AAT might be regulating the activity of these molecules at the posttranslational level or the amplitude of expression is low and variations are not easily detected. Histological Analysis of Pancreatic Islet Transplants. As noted above, QRT-PCR methods were successfully used to test the authenticity of gene array data concerning the effect of AAT treatment upon islet transplant gene expression events. To analyze the overarching conclusions reached by our experimental approach, we used histologic methods.
In keeping with analysis of islet function noted above in this islet transplant model, histological analysis revealed the presence of only a few intact antiinsulin-stained islets in marginal mass islet transplants harvested on day 3 from the controls (Fig. 4) . In contrast, islets harvested from AAT-treated recipients revealed many more intact, antiinsulin-stained islets at day 3 posttransplantation (Fig. 4) . As cleaved caspase-3 was detected in 70% of islets at day 3 posttransplantation in controls but in only 5% of islets in AAT-treated hosts (Fig. 4) , AAT affords protection from apoptosis and thereby accounts at least in part for the preservation of insulin + β cells (Fig. 4) . As the presence of islet homing CD3
+ T cells and F4/80 + activated macrophages/ monocytes (Fig. 4) was considerably reduced at day 3 posttransplantation in AAT-treated compared with control recipients, this pathological analysis supports the systems biology analysis. AAT treatment clearly dampens immune and inflammatory mechanisms linked to islet cell loss.
Discussion
Despite considerable promise, islet transplantation has not been widely instituted in the clinic at least in part because multiple donors are usually required to render a single diabetic recipient euglycemic. In contrast, transplantation with a single whole pancreas transplant is sufficient to obtain euglycemia. Compared with whole pancreas transplantation, there is excessive loss of islet transplant function by year 5 even among recipients whose islet transplants functioned well at 1 y posttransplantation (1). It is possible, if not probable, that these two problems are linked. We have previously demonstrated that transplantation of a marginal mass of autologous cynomolgus nonhuman primate islets (islets harvested from 70 to 80% partial pancreatectomy specimen) into nonautoimmune diabetic hosts leads to inexorable, insidious loss of graft function (4) . Insofar as the islet transplant procedures are associated with an outpouring of inflammatory cytokines (2, 3), we have now tested the ability of short-term treatment with AAT, a protein that exerts in vitro cytoprotectant effects upon islets (9, 15) and is a potent inhibitor of proinflammatory cytokine expression (9, 15) to protect a marginal mass of transplanted islets from nonimmunological graft loss. Islets are adversely effected by inflammatory cytokines (7) . The potential attractiveness of AAT treatment to provide islet cytoprotection is enhanced by observations that short-term AAT treatment restores euglycemia and islet self-tolerance in overtly T1D NOD mice (16) as well as prevents diabetes in NOD mice (17, 18) . AAT is an antiprotease and it seems reasonable that this activity is central to its antiinflammatory and cytoprotective effects. As there are many substrates for AAT the precise relevant target is uncertain.
To study the effect of AAT treatment, we turned to an inbred murine model to study graft function and survival in nonautoimmune diabetic mice receiving a marginal mass of syngeneic islet transplants. In this mouse model, only 10% of control diabetic recipients regained a euglycemic state short term and none enjoyed graft function lasting 10 d. Each AAT-treated host became euglycemic short term and 70% remained euglycemic for at least 60 d. A systems biology approach using genomewide microarrays and bioinformatics analysis was applied to analyze the effect of AAT at the molecular level. AAT treatment resulted in suppression of inflammation and immune-responserelated genes at day 3. Furthermore, network analysis linked most of the molecules down-regulated by AAT to inflammatory pathways as highlighted by the major hubs, e.g., TLR, IFN, TNF-α, and NF-κB. Whereas it is impractical if not impossible to Fig. 2 . Transcriptional profiling of islets from AAT-treated and control recipient mice day 3 posttransplantation. Heat map of the top differentially expressed genes in islets from AAT-treated compared with control hosts at day 3 posttransplantation is shown. Genes were identified in a supervised analysis using an LCB value >1.2 and fold change >1.5. Each column presents data from an individual AAT-treated or control mouse and each row represents a gene. Gene expression is shown by pseudocolor scale (−3 to 3), with red denoting high expression level and green denoting low expression level of a gene. Top chemokine receptors and cytokines down-regulated by AAT treatment are marked with an asterisk (*). Transcriptional profiling was performed on total RNA obtained from at least three separately conducted experiments.
independently validate each aspect of the systems biology and analysis, the major molecules implicated were confirmed by QRT-PCR and histopathology. At day 3 posttransplantation, the systems biology data indicated that AAT dampened intratransplant inflammation and immune activation. QRT-PCR confirmed the inhibitory effect of AAT treatment upon expression of key proinflammatory molecules by gene array profiling, whereas histologic analysis revealed better preservation of insulin + islet cells and a marked decrease in graft infiltration by CD3 + T cells and activated nonlymphocyte mononuclear leukocytes. Hyperglycemia is known to trigger increased expression of inflammatory cytokines (19) .
Under most circumstances, multiple human donors are required to obtain an islet cell mass sufficient to render a single patient with T1D euglycemic. An unexpectedly high rate of late human islet allograft failure at 5 y posttransplantation is noted despite a high success rate at 1 y (1). In preclinical models, islet transplants are particularly vulnerable when a marginal islet cell mass is transplanted (20) (21) (22) (23) . In short, the promise of islet cell transplantation in the clinic cannot be realized in the absence of engraftment of healthy and resilient islets. We hypothesized correctly that administration of AAT, an acute phase reactant that serves to quench adverse inflammation (16) and promote islet cytoprotection (10, 15, 16) would protect autologous islet transplants from destruction and thereby help create and preserve a euglycemic state. The beneficial effects of AAT were readily detectable at the molecular as well as functional levels. AAT may prove useful in human transplantation. The temptation to test the effects of AAT therapy in human islet transplantation is heightened with recognition that AAT (i) restores euglycemia and β-cell tolerance in frankly diabetic NOD mice (16) and (ii) creates tolerance to MHC mismatched mouse islet transplants (15) .
Materials and Methods
AAT. Aralast (α-proteinase inhibitor, human; Baxter Healthcare), an AAT product obtained from human blood, is a concentrate of this serum serineprotease inhibitor. This AAT product inhibits the enzymatic activity of neutrophil elastase, cathepsin G, proteinase 3, thrombin, trypsin, and chymotrypsin.
Mice. Donor and recipient C57BL/6 male mice were purchased from Jackson Laboratories at 4 wk of age and maintained under pathogen-free conditions at Harvard Medical School animal facility (Boston, MA). All animal studies are approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center. Pancreatic islets were prepared by the islet core facility of Joslin Diabetic Center (Boston).
Effect of AAT upon Function and Histology of Marginal Mass Syngeneic Islet
Transplants. C57BL/6 recipient mice 10-12 wk of age were rendered diabetic by a single dose of 250 mg/kg STZ (Sigma) 10-14 d pretransplantation. Recipient mice had at least three consecutive fasting tail vein blood glucose levels >400 mg/dL (Accu-Check blood glucose monitor; Roche), and 150-200 syngeneic islets were transplanted beneath the renal capsule in control vehicle and AAT-treated mice. In the absence of AAT treatment, 600 syngeneic islets are required to restore normoglycemia. Blood glucose levels were checked at the time of transplantation, 1 h transplantation, and then daily for 2 wk and three determinations per week thereafter. Graft failure i.e., extreme hyperglycemia, was defined as the first day of 3 consecutive days of blood glucose levels >200 mg/dL. Following the loss of graft function, recipient mice were killed and the transplanted islet graft and host pancreas were taken for histology and transcriptional profiling. AAT-treated mice received 2 mg i.p. AAT per mouse on day −1 and posttransplant days 2, 5, 8, and 11. Control mice received PBS on the same schedule. Measurement of insulin from pancreatic islets. Aliquots of hand-picked islets (200IEQ) prepared from the same pool were studied. We compared the insulin content in freshly prepared islets and those recovered at day 3 posttransplantation from AAT-treated and control-treated recipients. Islets were homogenized (glass homogenizer; Kontes) in 3 mL 0.2 M acid ethanol, stored at 40°C overnight, and centrifuged at 3,000 rpm (Eppendorf Centrifuge 5810R) at 40°C for 10 min. The supernatant was retained and stored at 200°C until ready for assay. The samples were analyzed using an ELISA immunoassay (Insulin Rat ELISA; ALPCO) at the following dilutions, 1:100, 1:1,000, and 1:5,000.
Transcriptional Profiling Data Analysis of AAT-Treated Islet Transplants. Syngeneic islet transplants were placed under the renal capsule of STZ-induced diabetic mice. The grafts were resected 3 d after administration of AAT or control vehicle to the transplant recipients. Total RNA was obtained from at least three separately conducted experiments to compare control and AATtreated syngeneic murine islet grafts. Transcriptional profiling was conducted as previously described using mouse genome 430 2.0 Affymetrix gene chips (24) . After array quality analysis (25) , all high-quality arrays were normalized using dChip algorithm and signal value for each transcript was summarized using the PM-only based signal modeling algorithm (26) . When comparing two groups of samples to identify genes enriched in a given phenotype, i.e., control islets vs. AAT-treated islets, genes with a 90% LCB of the FC between the two groups above 1.2 were considered to be differentially expressed (27) . To further reduce the false positive rate, the genes with mean FC of >1.5 between the treated and control group were considered differentially expressed.
DAVID software was used to identify significantly overrepresented gene ontology categories among differentially expressed genes, and related gene ontology categories were merged in clusters using the functional clustering module of DAVID (14, 28) .
To perform the analysis of interactive networks and pathways, a commercial systems biology oriented package, IPA 5.0, was used. The significance of an effect on the pathway was determined using Benjamini-Hochbergcorrected P value (29) (SI Materials and Methods). The focus molecules were identified from the integrated networks on the basis of degree of connectivity (number of interactions for each gene). The focus hubs with higher degrees of connectivity are considered critical for maintenance of the networks, suggesting that therapeutic targeting of these focus hubs may elicit the strongest impact.
Frozen Sections for Light Microscopy. In all instances, the kidney with a transplant was removed and placed for 1 h in 2% PFA (Electron Microscopy Sciences). The tissue was then washed with PBS, and placed in 30% sucrose solution overnight at 4°C. The graft area was carefully excised and placed in TBS tissue freezing medium (Triangle Biomedical Sciences). The tissue was then placed in a cassette containing freezing medium and the tissue was flash frozen. Specimens were coded and randomized so that blinded analysis of the sections could be performed. Serial 6-to 8-μm sections were cut Using anti-CD3 and F4/80 staining, the gross infiltration of T cells and activated macrophages and monocytes into the islets was observed only in control islets. Caspase staining shows that AAT treatment reduces the numbers of apoptotic islets considerably as compared to control islets.
through the entire graft site and alternate slides, each with one to two sections, were stained with hematoxylin-eosin (H&E) for routine assessment of the infiltrate and immunoperoxidase to detect endocrine and mononuclear leukocyte subsets.
cDNA Synthesis. Total RNA was converted into cDNA using TaqMan Reverse Transcription kit (Applied Biosystems).
Quantitative Real-Time PCR (QRT-PCR). QRT-PCR analysis was performed by a two-step process, a 15-cycle preamplification step (AmpliTaq DNA Polymerase kit; Applied Biosystems) followed by measurement of mRNA with an ABI PRISM 7900HT Sequence Detection system. For the measurement of mRNA levels of selected targets, the TaqMan primer sets were commercially purchased (Assay-on-demand; Applied Biosystems). Two-time QuantiFast Probe PCR Master mix for QRT-PCR was purchased from Qiagen. Amplification was carried out in a total volume of 20 μL for 40 cycles of 3 s at 95°C, 30 s at 60°C; initial enzyme activation was performed for 3 min at 95°C. mRNA copy numbers are normalized using 18S rRNA copy numbers (mRNA copies in 1 μg RNA/18S rRNA copy numbers). For normalizing target gene expression, 18s rRNA (housekeeping gene) expression was used. The expression measurements were performed on the RNA extracted from treated and control islets in duplicate.
Statistical Analysis. Results are presented as mean ± SD. Statistical differences were analyzed by Student's unpaired t test. For insulin measurement, statistical significance of differences among groups was calculated using oneway analysis of variance (ANOVA). Bonferroni's significant difference post hoc test was used for pairwise comparisons after ANOVA to correct for multiple testing.
